Noninvasive molecular subtyping kit and method for breast cancer

Abstract

The invention provides a noninvasive molecular subtyping kit and method for a breast cancer and aims to provide a kit which is simple to use and high in detection accuracy and a noninvasive molecularsubtyping method for a breast cancer, which makes samples easy to obtain, is simple in sampling process, good in clinical experience, capable of achieving processized operation and very suitable for clinical application and non-disease diagnosis purposes. The technical scheme of the invention is that the noninvasive molecular subtyping kit for the breast cancer comprises a plasma free DNA extraction reagent, a library construction reagent, a sequencing reagent and a sequencing chip. The method is based on high-throughput sequencing data of plasma free DNA, nucleosome footprint difference information of a promoter region in the whole genome range in the plasma free DNA is obtained by means of bioinformatic analysis, and thus noninvasive molecular subtyping of four categories of a lumen A type, a lumen B type, an HER2 enrichment type and basal cell type of a breast cancer patient is achieved according to the difference of footprint information. The invention belongs to the technical field of biology.

Description

technical field [0001] The present invention provides a non-invasive molecular typing product of breast cancer, specifically, a non-invasive molecular typing product of breast cancer based on plasma cell-free DNA high-throughput sequencing technology, and the present invention also relates to a construction method of the molecular product, Belongs to the field of biotechnology. Background technique [0002] Breast cancer is the most common invasive cancer in women. According to the report of the World Health Organization in 2015, there are about 1.15 million new cases of breast cancer and about 410,000 deaths worldwide every year, and the incidence rate is increasing year by year. Breast cancer is also the most common cancer among Chinese women. Every year, the number of new breast cancer cases and deaths in China account for 12.2% and 9.6% of the world's total respectively. [0003] The molecular classification of breast cancer is closely related to the treatment and prog...

AI Technical Summary

Problems solved by technology

This invasive diagnostic method increases patient suffering and the risk of tumor dissemination

In addition, due to the large heterogeneity of tumor tissues, the biopsy analysis of local punctures may cause biased results, and the pathological diagnosis of biopsy tissues also requires a good pathological theoretical basis and practical experience

Patients who need a second biopsy need to determine the site of tumor progression, and for patients who have undergone surgical resection, it is impossible to obtain usable tissue samples to judge prognosis and metastasis

Images